Eisai/Biogen’s Leqembi Will Launch Below Aduhelm At $26,500 Per Year
Available For Commercially Insured Patients By Mid-Month
Executive Summary
With accelerated approval granted and a supplemental filing for full approval in the FDA's hands, Eisai set a price it says is below the “societal value” its Alzheimer’s drug provides as it prepares to seek Medicare coverage. Labeling notably comes with no black box warning or safety restrictions despite various concerns.
You may also be interested in...
Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium
Lilly expects US approval of the anti-amyloid therapy by the end of the year. Full Phase III data were detailed at AAIC.
Biogen’s Adam Keeney Focuses On Dealmaking As Growth Strategy Is Made Over
Recently appointed head of corporate development in an ongoing leadership shakeup, Keeney is helping to shape Biogen’s sustainable growth strategy in neuroscience and beyond.
How Much Delay In Alzheimer’s Disease Progression Is Clinically Meaningful?
US FDA agrees with Eisai/Biogen that half a point change in cognitive scale, which sponsor says means a five month delay in decline, is a clinically meaningful benefit. But others contend the treatment effect is small and does not outweigh risk of brain bleeds.